Cell Viability Assays

OK Olga Kondrashova
MN Minh Nguyen
KS Kristy Shield-Artin
AT Anna V. Tinker
NT Nelson N.H. Teng
MH Maria I. Harrell
MK Michael J. Kuiper
GH Gwo-Yaw Ho
HB Holly Barker
MJ Maria Jasin
RP Rohit Prakash
EK Elizabeth M. Kass
MS Meghan R. Sullivan
GB Gregory J. Brunette
KB Kara A. Bernstein
RC Robert L. Coleman
AF Anne Floquet
MF Michael Friedlander
GK Ganessan Kichenadasse
DO David M. O'Malley
AO Amit Oza
JS James Sun
LR Liliane Robillard
LM Lara Maloney
HG Heidi Giordano
MW Matthew J. Wakefield
SK Scott H. Kaufmann
AS Andrew D. Simmons
TH Thomas C. Harding
MR Mitch Raponi
IM Iain A. McNeish
ES Elizabeth M. Swisher
KL Kevin K. Lin
CS Clare L. Scott
ask Ask a question
Favorite

Endpoint viability assays were performed using the CellTiter-Glo (Promega) assay according to the manufacturer's protocol. Briefly, cells were seeded at 600 to 800 cells per in 384-well plates or 2,000 cells in 96-well plates and allowed to establish overnight before adding treatments. Cells were treated for 6 to 7 days with compounds, over a range of concentrations, then the assay was terminated and viability assessed using luminescence detection on a Victor X4 plate reader (Perkin Elmer). Luminescence was normalized to DMSO control, and IC50 values were calculated using a sigmoidal dose–response curve fit analysis (Prism software, GraphPad).

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A